
Spectrum Pharmaceuticals SPPI
Quartalsbericht 2023-Q1
hinzugefügt 11.05.2023
Spectrum Pharmaceuticals Betriebsaufwand 2011-2026 | SPPI
Betriebsaufwand Jährlich Spectrum Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 170 M | 141 M | 214 M | 178 M | 172 M | 176 M | 191 M | 166 M | 141 M | 104 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 214 M | 104 M | 165 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M | ||
|
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | ||
|
Esperion Therapeutics
ESPR
|
343 M | $ 3.13 | 0.55 % | $ 651 M | ||
|
Exelixis
EXEL
|
598 M | $ 48.2 | 8.51 % | $ 13.1 B | ||
|
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | ||
|
Fortress Biotech
FBIO
|
125 M | $ 2.53 | 2.85 % | $ 70.6 M | ||
|
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | ||
|
Galapagos NV
GLPG
|
709 M | $ 28.81 | 1.48 % | $ 2.69 B | ||
|
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | ||
|
Genmab A/S
GMAB
|
67.9 M | $ 27.95 | 1.5 % | $ 17.2 B | ||
|
Genprex
GNPX
|
18 M | $ 0.91 | 2.24 % | $ 849 K | ||
|
Grifols, S.A.
GRFS
|
1.64 B | $ 8.4 | 1.63 % | $ 6.83 B | ||
|
InflaRx N.V.
IFRX
|
52.4 M | $ 2.51 | 27.16 % | $ 152 M | ||
|
Ionis Pharmaceuticals
IONS
|
752 M | $ 77.0 | 2.33 % | $ 12.3 B | ||
|
BioNTech SE
BNTX
|
512 M | $ 94.64 | -0.9 % | $ 27.2 B | ||
|
Kamada Ltd.
KMDA
|
69 K | $ 8.29 | 0.91 % | $ 260 M | ||
|
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - | ||
|
Checkmate Pharmaceuticals
CMPI
|
61.5 M | - | - | $ 231 M | ||
|
Kymera Therapeutics
KYMR
|
389 M | $ 85.79 | 3.72 % | $ 7.25 B | ||
|
Kazia Therapeutics Limited
KZIA
|
8.82 M | $ 13.58 | 0.97 % | $ 1.8 B | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
115 M | $ 231.58 | -0.31 % | $ 4.24 B | ||
|
INmune Bio
INMB
|
47.4 M | $ 1.54 | - | $ 38.1 M | ||
|
Liquidia Corporation
LQDA
|
59.6 | $ 41.64 | 3.75 % | $ 3.58 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
708 M | $ 22.58 | 1.03 % | $ 3.74 B | ||
|
Mirum Pharmaceuticals
MIRM
|
543 M | $ 107.36 | 1.46 % | $ 5.39 B | ||
|
MannKind Corporation
MNKD
|
88 M | $ 3.61 | 26.17 % | $ 1.1 B | ||
|
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 3.46 | -1.14 % | $ 5.7 M | ||
|
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | ||
|
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | ||
|
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | ||
|
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | ||
|
Arcutis Biotherapeutics
ARQT
|
137 M | $ 24.0 | 2.46 % | $ 3.05 B | ||
|
Nanobiotix S.A.
NBTX
|
43.4 M | $ 41.6 | 19.64 % | $ 286 B | ||
|
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | ||
|
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B |